Armata adds $25M Innoviva loan, posts Q1 loss
Rhea-AI Filing Summary
Armata Pharmaceuticals entered a new secured term loan agreement with Innoviva Strategic Opportunities for $25 million at a 14.0% annual interest rate, maturing on January 11, 2029, guaranteed by its domestic subsidiaries and secured by substantially all assets. The company also reported first quarter 2026 results: grant and award revenue was $0.8 million and research and development expenses were $6.1 million, reflecting continued investment in its AP‑SA02 bacteriophage program. Net loss widened sharply to $115.3 million, largely driven by a $101.1 million unfavorable change in the fair value of a Convertible Loan, while cash and cash equivalents declined to $4.8 million as of March 31, 2026. Armata highlighted FDA Qualified Infectious Disease Product and Fast Track Designation for AP‑SA02 and its goal to advance this candidate into a Phase 3 study in complicated S. aureus bacteremia.
Positive
- None.
Negative
- Large Q1 2026 net loss and fair value hit: Net loss reached $115.3 million, driven primarily by a $101.1 million unfavorable change in the fair value of the Convertible Loan, far above the prior-year loss of $6.5 million.
- Highly leveraged balance sheet and deficit: Total liabilities were $381.4 million against total assets of $69.8 million, resulting in a stockholders’ deficit of $311.6 million as of March 31, 2026.
- Low cash relative to burn: Cash and cash equivalents were $4.8 million at quarter-end, while net cash used in operating activities was $5.8 million for Q1 2026, indicating limited runway without additional financing.
Insights
High-cost debt adds liquidity but highlights leverage and losses.
Armata has taken on a secured term loan of $25 million from Innoviva at a steep 14.0% interest rate, maturing in 2029. The facility is guaranteed by domestic subsidiaries and secured by substantially all assets, adding meaningful structural leverage.
For Q1 2026, grant revenue was $0.8 million against operating expenses of $9.6 million, producing an operating loss of $8.8 million. The headline net loss of $115.3 million was driven mainly by a $101.1 million negative fair value adjustment on a sizable Convertible Loan.
Liabilities totaled $381.4 million versus total assets of $69.8 million, resulting in stockholders’ deficit of $311.6 million. Cash and cash equivalents were $4.8 million as of March 31, 2026, while operating cash outflow was $5.8 million for the quarter, underscoring reliance on external funding such as the Innoviva credit facility.
8-K Event Classification
Key Figures
Key Terms
material definitive agreement regulatory
Qualified Infectious Disease Product medical
Fast Track Designation medical
Biologics License Application regulatory
Convertible Loan financial
current Good Manufacturing Practices technical
Earnings Snapshot
FAQ
What credit facility did Armata Pharmaceuticals (ARMP) enter into in May 2026?
How did Armata Pharmaceuticals (ARMP) perform financially in Q1 2026?
What were Armata Pharmaceuticals’ (ARMP) Q1 2026 revenues and operating expenses?
What is Armata Pharmaceuticals’ (ARMP) cash position and leverage as of March 31, 2026?
What regulatory milestones has Armata Pharmaceuticals (ARMP) achieved for AP-SA02?
How much cash did Armata Pharmaceuticals (ARMP) use in operations during Q1 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
(
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | | Trading Symbol(s) | | Name of Each Exchange on Which Registered |
Item 1.01Entry into a Material Definitive Agreement.
On May 13, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029. Repayment of the Loan is guaranteed by the Company’s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.
The May 2026 Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The May 2026 Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the May 2026 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company’s operating budget.
The foregoing description of the May 2026 Credit Agreement is qualified in its entirety by the full text of such document, which is filed as Exhibit 10.1, respectively, and is incorporated herein by reference.
Item 2.02Results of Operations and Financial Condition.
On May 13, 2026, the Company announced its financial results for the three months ended March 31, 2026, in the press release furnished hereto as Exhibit 99.1.
The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The disclosure set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 7.01Regulation FD Disclosure.
On May 13, 2026, the Company issued a press release announcing the matters discussed under Item 1.01 of this Current Report on Form 8-K. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit | | Description |
10.1 | Credit and Security Agreement, dated May 12, 2026. | |
99.1 | Press Release, dated May 13, 2026. | |
104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 13, 2026 | Armata Pharmaceuticals, Inc. | |
By: | /s/ David House | |
Name: | David House | |
Title: | Senior Vice President, Finance and Principal Financial Officer | |
Exhibit 99.1
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029
LOS ANGELES, California, May 13, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update.
“Our top priority in 2026 is advancing Armata’s lead Staphylococcus aureus (“S. aureus”) therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia (“SAB”),” said Dr. Deborah Birx, Chief Executive Officer of Armata. “We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application (“BLA”) submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection. We believe this program will establish a foundation for expanding our phage platform into additional indications. Ultimately, we believe there is a significant opportunity for this innovative antibacterial technology to have a broad impact on antimicrobial resistance, which represents one of the significant public health challenges of modern medicine.”
“I also want to highlight other important recent developments including the granting by the U.S. Food and Drug Administration (the “FDA”) of both Qualified Infectious Disease Product (“QIDP”) and Fast Track Designation for AP-SA02. Additionally, the recent appointment of Dr. Daniel Gilmer to Armata’s Board brings commercial leadership and experience as we continue to move toward potential registration and commercialization. We are pleased to have the ongoing backing of Innoviva, our largest shareholder who has supported us since 2020, in providing additional financing that will help us to advance AP-SA02, and we are continuing to pursue additional sources of funding, including non-dilutive sources,” concluded Dr. Birx.
First Quarter 2026 and Recent Developments:
Clinical and Regulatory
| ● | Preparations are ongoing to advance AP-SA02, a novel intravenously administered multi-phage therapeutic, into a Phase 3 superiority study in complicated SAB caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin resistant S. aureus (“MRSA”). |
| o | The study is expected to initiate in the second half of 2026. |
| ● | Announced that the FDA granted Fast Track Designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA, advancing AP-SA02 on a faster path to potential approval and patient access. |
| o | Facilitates the development and expedites the review of investigational therapies that treat serious conditions and fill an unmet medical need. |
| o | Provides for more frequent interactions with the FDA regarding all aspects of a designated drug’s clinical development program, supporting a more efficient path to registration. |
| o | Allows for rolling review of a BLA, meaning completed sections may be submitted and reviewed on an ongoing basis rather than waiting for the full application. |
| o | Fast Track-designated programs may also be eligible for Accelerated Approval and Priority Review if supported by clinical data at the time of BLA submission, further supporting a faster path to potential approval and patient access. |
| ● | Announced that the FDA granted AP-SA02 for intravenous use as a QIDP for adjunct treatment of complicated SAB caused by MSSA or MRSA. |
| o | To achieve QIDP designation, a drug candidate must be intended to treat serious or life-threatening infections, particularly those caused by bacteria and fungi that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. |
| o | The QIDP designation makes AP-SA02 eligible to benefit from certain incentives for the development of new antibacterials provided under the Generating Antibiotic Incentives Now (GAIN) Act, including an additional five-year extension of Hatch-Waxman market exclusivity. |
Financial
| ● | On May 12, 2026, entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata’s largest shareholder, for a loan of $25.0 million that will mature on January 11, 2029. |
| o | Proceeds from the transaction will be used to continue to advance development of AP-SA02. |
| ● | On January 23, 2026, Armata entered into amendments to the March 2025 Credit Agreement, the 2024 Credit Agreement, the 2023 Credit Agreement, and the Convertible Credit Agreement with Innoviva Strategic Opportunities LLC, extending the maturity dates to June 1, 2027. In exchange for such amendments, the Company also amended certain outstanding Innoviva warrants to extend their expiration dates to January 26, 2031, and amended the related voting agreement to align with the revised warrant expiration date or FDA approval, as applicable. |
Corporate Governance
| ● | Appointed biopharmaceutical commercial executive Daniel B. Gilmer, Ph.D. to Board of Directors. |
| o | Dr. Gilmer brings 20 years of experience in healthcare commercialization (Pfizer, Inc.), management consulting (McKinsey & Co.), and academic research (Rockefeller University, National Institutes of Health). |
| o | At Pfizer: |
| ◾ | Most recently led an organization responsible for quality and promotional review across 50+ U.S. brands. |
| ◾ | Launched PAXLOVIDTM following approval by the FDA. |
| ◾ | In Inflammation & Immunology Commercial Development, helped shape strategy for a portfolio of rheumatology and immunology assets. |
| ◾ | Contributed to COVID-19 vaccine-enabling operating model and R&D portfolio strategy. |
| o | Authored multiple peer-reviewed publications on phage lysins and antimicrobial resistance. |
Presentations and Publications
| ● | Further advanced bacteriophage science through presentations and publications. |
| o | Published a paper, titled, “Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection" in Communications Biology, a peer-reviewed journal from Nature Portfolio. The paper describes the structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02. |
| o | Presented at the 8th Annual Bacteriophage Therapy Summit held on March 24-26 in London, UK. |
First Quarter 2026 Financial Results
Grant and Award Revenue. The Company recognized grant and award revenue of $0.8 million for the three months ended March 31, 2026, as compared to $0.5 million in the comparable period in 2025. This represents the Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of SAB.
Research and Development. Research and development expenses for the three months ended March 31, 2026 were approximately $6.1 million compared to approximately $5.4 million for the comparable period in 2025. The increase was primarily due to a large credit recorded in the prior year period related to AP-PA02 NCFB trial costs. Excluding this prior period credit, research and development expenses increased modestly period over period, reflecting ongoing AP-SA02 program activities.
General and Administrative. General and administrative expenses for the three months ended March 31, 2026 were approximately $3.5 million, compared to approximately $3.3 million for the comparable period in 2025. The increase of $0.2 million is primarily related to an increase in stock-based compensation expense.
Loss from Operations. Loss from operations for the three months ended March 31, 2026 was approximately $8.8 million, compared to a loss from operations of approximately $8.2 million for the comparable period in 2025.
Net Loss. The net loss for the first quarter of 2026 was $115.3 million, or $3.16 loss per share on a basic and diluted basis, as compared to a net loss of $6.5 million, or $0.18 loss per share basic and $0.20 loss per share diluted, for the comparable period in 2025.
Cash and Cash Equivalents. As of March 31, 2026, Armata held approximately $4.8 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025.
As of May 8, 2026, approximately 36.7 million common shares were outstanding.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
Armata Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| | March 31, 2026 | | December 31, 2025 | | ||
Assets | | | | | | | |
Current assets | | | | | | | |
Cash and cash equivalents | | $ | 4,754 | | $ | 8,688 | |
Prepaid expenses and other current assets | |
| 1,145 | |
| 1,508 | |
Other receivables | | | 47 | | | 472 | |
Total current assets | |
| 5,946 | |
| 10,668 | |
Property and equipment, net | |
| 11,780 | |
| 12,194 | |
Operating lease right-of-use asset | |
| 33,395 | |
| 33,911 | |
Intangible assets, net | | | 13,746 | | | 13,746 | |
Other long term assets | |
| 4,933 | |
| 6,363 | |
Total assets | | $ | 69,800 | | $ | 76,882 | |
| | | | | | | |
Liabilities and stockholders’ deficit | |
| | |
| | |
Accounts payable, accrued and other current liabilities | | $ | 9,228 | | $ | 8,947 | |
Total current liabilities | | 9,228 | | 8,947 | | ||
Convertible loan, non-current | | | 254,922 | | | 153,860 | |
Term debt, non-current | | | 87,976 | | | 103,061 | |
Operating lease liabilities, net of current portion | | | 26,183 | | | 26,533 | |
Deferred tax liability | | | 3,077 | | | 3,077 | |
Total liabilities | |
| 381,386 | |
| 295,478 | |
Total stockholders’ deficit | |
| (311,586) | |
| (218,596) | |
Total liabilities and stockholders’ deficit | | $ | 69,800 | | $ | 76,882 | |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended March 31, | ||||
| 2026 | | 2025 | ||
Grant and award revenue | $ | 789 | | $ | 491 |
Operating expenses | | | | | |
Research and development |
| 6,111 | | | 5,429 |
General and administrative |
| 3,463 | | | 3,253 |
Total operating expenses | | 9,574 | | | 8,682 |
Operating loss |
| (8,785) | |
| (8,191) |
Other income (expense) |
| | |
| |
Interest income | | 60 | | | 59 |
Interest expense | | (5,559) | | | (3,602) |
Change in fair value of the Convertible Loan | | (101,062) | | | 5,203 |
Total other income (expense), net |
| (106,561) | |
| 1,660 |
Net loss | $ | (115,346) | | $ | (6,531) |
Per share information: | | | | | |
Net loss per share, basic | $ | (3.16) | | $ | (0.18) |
Weighted average shares outstanding, basic | | 36,530,284 | | | 36,184,802 |
Net loss per share, diluted | $ | (3.16) | | $ | (0.20) |
Weighted average shares outstanding, diluted | | 36,530,284 | | | 59,478,662 |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Three Months Ended March 31, | |||
2026 | 2025 | ||
Operating activities: |
|
|
|
Net loss | $ (115,346) | $ (6,531) | |
Adjustments required to reconcile net loss to net cash used in operating activities: |
|
|
|
Depreciation expense | 457 | 377 | |
Stock-based compensation expense | 1,075 |
| 781 |
Change in fair value of the Convertible Loan | 101,062 | (5,203) | |
Non-cash interest expense | 5,555 |
| 3,596 |
Change in right-of-use asset | 516 | 597 | |
Changes in operating assets and liabilities | 899 |
| (1,197) |
Net cash used in operating activities | (5,782) | (7,580) | |
Investing activities: |
|
|
|
Purchases of property and equipment | (63) | (99) | |
Net cash used in investing activities | (63) |
| (99) |
Financing activities: |
|
| |
Proceeds from issuance of term debt, net of issuance costs | — |
| 10,000 |
Payments for taxes related to net share settlement of equity awards | (63) | (14) | |
Proceeds from exercise of stock options | 704 |
| — |
Net cash provided by financing activities | 641 | 9,986 | |
Net (decrease) increase in cash, cash equivalents and restricted cash | (5,204) |
| 2,307 |
Cash, cash equivalents and restricted cash, beginning of period | 14,078 | 14,771 | |
Cash, cash equivalents and restricted cash, end of period | $ 8,874 |
| $ 17,078 |
Cash and cash equivalents | $ 4,754 |
| $ 11,688 |
Restricted cash | 4,120 | 5,390 | |
Cash, cash equivalents and restricted cash | $ 8,874 |
| $ 17,078 |